Mymee
Pre-clinicalMymee identifies unique triggers in the exposome for patients with rheumatoid arthritis, lupus, psoriatic arthritis, ankylosing spondylitis and long COVID who have uncontrolled symptoms despite treatment.
Founded
2016
Focus
Digital HealthAI / Machine Learning
About
Mymee identifies unique triggers in the exposome for patients with rheumatoid arthritis, lupus, psoriatic arthritis, ankylosing spondylitis and long COVID who have uncontrolled symptoms despite treatment.
Funding History
2Total raised: $10.5M
Series A$8MGalen PartnersMar 15, 2021
Seed$2.5MUndisclosedJun 15, 2018
Company Info
TypePrivate
Founded2016
LocationNew York, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile